Clinical Trials Logo

Purpura, Thrombocytopenic clinical trials

View clinical trials related to Purpura, Thrombocytopenic.

Filter by:

NCT ID: NCT03275454 Completed - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

Start date: August 14, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia.

NCT ID: NCT03258866 Completed - Clinical trials for Immune Thrombocytopenia

The Study of Different Dose Rituximab in the Treatment of ITP

Start date: January 1, 2010
Phase: Phase 4
Study type: Interventional

The project was undertaking by Qilu Hospital of Shandong University in China. In order to compare the efficacy, safety and response duration of different dose of rituximab in patients primary immune thrombocytopenia(pITP).

NCT ID: NCT03222843 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Start date: June 30, 2017
Phase: Phase 3
Study type: Interventional

A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain platelet counts 50~250×109/L

NCT ID: NCT03219723 Completed - Clinical trials for Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other

Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"

Start date: September 1, 2015
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

NCT ID: NCT02914054 Completed - ITP Clinical Trials

Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone

Start date: October 1, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

In this prospective, randomized, controlled clinical trial investigators' aim was to compare the efficacy and the adverse effect of 3 therapy cycles of HD-DXM versus conventional treatment with PDN for untreated adult patients with ITP. In this study standardized criteria and definitions were used according to consensus international working group guideline for ITPto compare clinical outcomes of the two corticosteroid treatment regimens and determine the superior regimen as a first line strategy for new primary ITP in adults

NCT ID: NCT02891109 Completed - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

Regulatory B Cells and Chronic Immune Thrombocytopenia

PTIREG
Start date: January 2015
Phase: N/A
Study type: Observational

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown.

NCT ID: NCT02878603 Completed - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

Start date: October 6, 2016
Phase: Phase 3
Study type: Interventional

The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).

NCT ID: NCT02553317 Completed - Clinical trials for Acquired Thrombotic Thrombocytopenic Purpura

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

HERCULES
Start date: November 2015
Phase: Phase 3
Study type: Interventional

The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

NCT ID: NCT02334813 Completed - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia

EIS2002
Start date: July 2002
Phase: Phase 3
Study type: Interventional

Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6 mg/kg/d, days 1-4; arm B). The primary endpoint is duration of remission defined as platelets ≥50/nl.

NCT ID: NCT02281370 Completed - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects

Start date: November 5, 2014
Phase: Phase 1
Study type: Interventional

A drug-drug interaction study between eltrombopag and cyclosporine is being conducted to support the use of these drugs together in subjects, such as those with severe aplastic anemia or immune thrombocytopenia purpura. The primary objective of the study is to evaluate the effect of cyclosporine on the pharmacokinetics of eltrombopag. This is a Phase I, open-label, randomized, three-period cross-over study in healthy adult subjects. The study consists of a screening visit and three treatment periods. All subjects will be randomized to receive one of the three treatments in each treatment period separated by washout periods of 3-10 days. The total duration of a subject's participation in the study from screening to final discharge is up to approximately 6 weeks (assuming 3 day washouts between treatment periods). Approximately 39 healthy subjects will be enrolled with the goal of completing at least 10 subjects per sequence (total 30).